Wellington Partners

Wellington Partners

  • Home
  • Team
  • Approach
  • Portfolio
  • News
  • Contact

News

FierceBiotech names Confo Therapeutics as one of its “Fierce 15” Biotech Companies of 2019

Details
Published: 23 September 2019
  • portfolio-news

Confo Therapeutics today announces that it has been named by FierceBiotech as one of 2019’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry. Confo Therapeutics is building a portfolio of new medicines based on its proprietary Confo® technology. The technology makes use of antibody fragments or “ConfoBodiesTM” to stabilize G-protein coupled receptors (GPCRs) in their functional conformation, providing a superior starting point for drug design.

Themis raises EUR 40 Million in Series D financing round backed by US/EU consortium

Details
Published: 18 September 2019
  • portfolio-news

Themis announced today the closing of a Series D financing round totaling EUR 40 million (USD 44 million). The proceeds from this Series D round will be used to accelerate the company’s pivotal Phase 3 clinical trial program for its Chikungunya vaccine and to support further expansion into oncology indications using its proprietary measles vaccine vector platform. Concurrent with the financing, Dr. Walter Stockinger, Managing Partner at Hadean Ventures, will join Themis’ Supervisory Board. 

Adrenomed Supervisory Board appoints Jens Schneider-Mergener as CEO & Jens Zimmermann (CMO) joins the Executive Board

Details
Published: 29 August 2019
  • portfolio-news

Adrenomed announced today that its Supervisory Board has appointed two new members of the Executive Board. Dr. Jens Schneider-Mergener is CEO effective August 1, 2019 and Dr. Jens Zimmerman (CMO) joined the Executive Board effective July 1, 2019. Dr. Schneider-Mergener will succeed Dr. Gerald Möller, who is designated to join Adrenomed’s Supervisory Board. Dr. Schneider-Mergener brings more than 25 years of experience in the biotechnology industry, with a proven track record of successfully transforming a research-stage biotech business into a fully-integrated pharmaceutical company. 

  1. Immatics and Celgene enter strategic collaboration to develop novel adoptive cell therapies
  2. Themis announces exclusive license and research collaboration agreement with MSD to develop vaccine candidates
  3. Wellington Partners raises EUR 210 million life science fund
  4. Quanta raises $48 million in Series C funding round

Page 4 of 25

  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next
  • End
© Wellington Partners, 2019.
  • WP Technology Funds
  • Contact
  • Imprint
  • Privacy